-
PDF
- Split View
-
Views
-
Cite
Cite
SV Konstantinides, A Torbicki, G Agnelli, N Danchin, D Fitzmaurice, N Galiè, JSR Gibbs, MV Huisman, M Humbert, N Kucher, I Lang, M Lankeit, J Lekakis, C Maack, E Mayer, N Meneveau, A Perrier, P Pruszczyk, LH Rasmussen, TH Schindler, P Svitil, A Vonk Noordegraaf, JL Zamorano, M Zompatori, Authors/Task Force Members, Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism, European Heart Journal, Volume 36, Issue 39, 14 October 2015, Page 2642, https://doi.org/10.1093/eurheartj/ehu479
Close - Share Icon Share
[Eur Heart J 2014;35:3033–73, doi:10.1093/eurheartj/ehu283]
The published version of these Guidelines referred to 317 000 VTE-related deaths related in six countries of the European Union. The correct number is 370 000 deaths.
In addition, in section 5.2.3, in the paragraph concerning The Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy (AMPLIFY) study, the statement “inhibitor apixaban (10 mg twice daily for 7 days, followed by 5 mg once daily)” is incorrect. The correct phrase should be: “inhibitor apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily)…”
